
What is claimed is:

1. Use of a compound of Formula (I):



I,

or an enantiomer, mixture of enantiomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating non-Hodgkin lymphoma (NHL) in combination with a second therapeutic agent in a subject, wherein the second therapeutic agent is tafasitamab, obinutuzumab, or tazemetostat.

2. The use of claim 1, provided that when the second therapeutic agent is tazemetostat, the NHL is follicular lymphoma (FL), primary central nervous system lymphoma (PCNSL), or mantle cell lymphoma (MCL).

3. The use of claim 1, wherein the NHL is diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), mantle cell lymphoma (MCL), or primary central nervous system lymphoma (PCNSL).

4. The use of any one of claims 1 to 3, wherein the NHL is relapsed or refractory NHL.

5. The use of claim 4, wherein the NHL is relapsed or refractory DLBCL, relapsed or refractory FL, relapsed or refractory MCL, or relapsed or refractory PCNSL.

6. The use of claim 4 or 5, wherein the subject has received at least one prior line of therapy.

7. The use of claim 4 or 5, wherein the subject has received at least two prior lines of

therapy.

8. The use of claim 4 or 5, wherein the subject has received one to three systemic regimens, and wherein at least one of the systemic regimens is an anti-CD20 therapy.

9. The use of any one of claims 1 to 3, wherein the NHL is newly diagnosed.

10. The use of any one of claims 1 to 9, wherein the NHL is characterized by the presence of an Enhancer of Zeste Homolog 2 (EZH2) mutation.

11. The use of any one of claims 1 to 10, wherein the second therapeutic agent is tafasitamab.

12. The use of claim 11, wherein tafasitamab is to be administered via intravenous infusion.

13. The use of claim 11 or 12, wherein tafasitamab is to be administered in an amount of about 12 mg/kg of the body weight of the subject.

14. The use of any one of claims 11 to 13, wherein tafasitamab is to be administered on days 1, 4, 8, 15, and 22 of the first 28-day cycle, days 1, 8, 15, and 22 of the second and third 28-day cycles, and days 1 and 15 of the subsequent 28-day cycle(s).

15. The use of any one of claims 1 to 10, wherein the second therapeutic agent is obinutuzumab.

16. The use of claim 15, wherein obinutuzumab is to be administered via intravenous infusion.

17. The use of claim 15 or 16, wherein obinutuzumab is to be administered in an amount of about 1000 mg.

18. The use of any one of claims 15 to 17, wherein obinutuzumab is to be administered on days 1, 8 and 15 of the first 28-day cycle and day 1 of the second to the sixth 28-day cycles.

19. The use of any one of claims 1 to 10, wherein the second therapeutic agent is tazemetostat.

20. The use of claim 19, wherein tazemetostat is to be administered orally.

21. The use of claim 19 or 20, wherein tazemetostat is to be administered with food.

22. The use of claim 19 or 20, wherein tazemetostat is to be administered without food.

23. The use of any one of claims 19 to 22, wherein tazemetostat is to be administered in an amount of about 400 mg, about 600 mg or about 800 mg.

24. The use of any one of claims 19 to 23, wherein tazemetostat is to be administered twice daily.

25. The use of any one of claims 1 to 24, wherein a compound of Formula (I), or a pharmaceutically acceptable salt thereof, is used in the manufacture of the medicament.

26. The use of claim 25, wherein a hydrochloride salt of a compound of Formula (I) is used in the manufacture of the medicament.

27. The use of any one of claims 1 to 26, wherein the medicament is manufactured to be administered orally.

28. The use of claim 27, wherein the medicament is manufactured to be administered when the subject is fed.

29. The use of claim 27, wherein the medicament is manufactured to be administered when the subject is fasted.

30. The use of any one of claims 1 to 29, wherein the medicament is manufactured to be administered

(a) once daily for 5 days followed by 2 days of rest;

(b) once daily for 5 days followed by 9 days of rest;
(c) once daily for 7 days followed by 7 days of rest;
(d) once daily for 14 days followed by 14 days of rest; or
(e) once daily for 21 days followed by 7 days of rest.

31. The use of any one of claims 1 to 29, wherein the medicament is manufactured to be administered on days 1 to 5 of a 7-day cycle, on days 1 to 5 of a 14-day cycle, on days 1 to 7 of a 14-day cycle, on days 1 to 10 of a 14-day cycle, on days 1 to 14 of a 28-day cycle, on days 1 to 21 of a 28-day cycle, on days 1 to 5, days 8 to 12, days 15 to 19, and days 22 to 26 of a 28-day cycle, on days 1 to 5 and days 15 to 19 of a 28-day cycle, on days 1 to 7 and days 15 to 21 of a 28-day cycle, or on days 1 to 10 and days 15 to 24 of a 28-day cycle.

32. The use of any one of claims 1 to 31, wherein the medicament is manufactured for the compound to be administered in an amount of about 0.1 mg, about 0.2 mg, about 0.4 mg, about 0.6 mg, about 0.8 mg, about 1.2 mg or about 1.6 mg per day.

33. The use of claim 1, wherein:

(1) (i) the medicament is manufactured to be administered in cycles of once daily for 5 days followed by 2 days of rest, starting on day 1 of the first 28-day cycle; and (ii) tafasitamab is to be administered on days 1, 4, 8, 15, and 22 of the first 28-day cycle, days 1, 8, 15, and 22 of the second and third 28-day cycles, and days 1 and 15 of the subsequent 28-day cycle(s), wherein the NHL is relapsed or refractory DLBCL;

(2) (i) the medicament is manufactured to be administered in cycles of once daily for 5 days followed by 9 days of rest, starting on day 1 of the first 28-day cycle; and (ii) tafasitamab is to be administered on days 1, 4, 8, 15, and 22 of the first 28-day cycle, days 1, 8, 15, and 22 of the second and third 28-day cycles, and days 1 and 15 of the subsequent 28-day cycle(s), wherein the NHL is relapsed or refractory DLBCL;

(3) (i) the medicament is manufactured to be administered in cycles of once daily for 7 days followed by 7 days of rest, starting on day 1 of the first 28-day cycle; and (ii) tafasitamab is to be administered on days 1, 4, 8, 15, and 22 of the first 28-day cycle, days 1, 8, 15, and 22 of the second and third 28-day cycles, and days 1 and 15 of the subsequent 28-day cycle(s), wherein the NHL is relapsed or refractory DLBCL;

(4) (i) the medicament is manufactured to be administered in cycles of once daily for 14 days followed by 14 days of rest, starting on day 1 of the first 28-day cycle; and (ii) tafasitamab is to be administered on days 1, 4, 8, 15, and 22 of the first 28-day cycle, days 1, 8, 15, and 22 of the second and third 28-day cycles, and days 1 and 15 of the subsequent 28-day cycle(s), and then once every two weeks, wherein the NHL is relapsed or refractory DLBCL;

(5) (i) the medicament is manufactured to be administered in cycles of once daily for 21 days followed by 7 days of rest, starting on day 1 of the first 28-day cycle; and (ii) tafasitamab is to be administered on days 1, 4, 8, 15, and 22 of the first 28-day cycle, days 1, 8, 15, and 22 of the second and third 28-day cycles, and days 1 and 15 of the subsequent 28-day cycle(s), wherein the NHL is relapsed or refractory DLBCL;

(6) (i) the medicament is manufactured to be administered in cycles of once daily for 5 days followed by 2 days of rest, starting on day 1 of the first 28-day cycle; and (ii) obinutuzumab is to be administered on days 1, 8 and 15 of the first 28-day cycle and day 1 of the second to the sixth 28-day cycles, wherein the NHL is relapsed or refractory FL;

(7) (i) the medicament is manufactured to be administered in cycles of once daily for 5 days followed by 9 days of rest, starting on day 1 of the first 28-day cycle; and (ii) obinutuzumab is to be administered on days 1, 8 and 15 of the first 28-day cycle and day 1 of the second to the sixth 28-day cycles, wherein the NHL is relapsed or refractory FL;

(8) (i) the medicament is manufactured to be administered in cycles of once daily for 7 days followed by 7 days of rest, starting on day 1 of the first 28-day cycle; and (ii) obinutuzumab

is to be administered on days 1, 8 and 15 of the first 28-day cycle and day 1 of the second to the sixth 28-day cycles, wherein the NHL is relapsed or refractory FL;

(9) (i) the medicament is manufactured to be administered in cycles of once daily for 14 days followed by 14 days of rest, starting on day 1 of the first 28-day cycle; and (ii) obinutuzumab is to be administered on days 1, 8 and 15 of the first 28-day cycle and day 1 of the second to the sixth 28-day cycles, wherein the NHL is relapsed or refractory FL;

(10) (i) the medicament is manufactured to be administered in cycles of once daily for 21 days followed by 7 days of rest, starting on day 1 of the first 28-day cycle; and (ii) obinutuzumab is to be administered on days 1, 8 and 15 of the first 28-day cycle and day 1 of the second to the sixth 28-day cycles, wherein the NHL is relapsed or refractory FL;

(11) (i) the medicament is manufactured to be administered in cycles of once daily for 5 days followed by 2 days of rest, starting on day 1 of the first 28-day cycle; and (ii) tazemetostat is to be administered twice daily starting on day 1 of the first 28-day cycle, wherein the NHL is relapsed or refractory DLBCL or relapsed or refractory FL;

(12) (i) the medicament is manufactured to be administered in cycles of once daily for 5 days followed by 9 days of rest, starting on day 1 of the first 28-day cycle; and (ii) tazemetostat is to be administered twice daily starting on day 1 of the first 28-day cycle, wherein the NHL is relapsed or refractory DLBCL or relapsed or refractory FL;

(13) (i) the medicament is manufactured to be administered in cycles of once daily for 7 days followed by 7 days of rest, starting on day 1 of the first 28-day cycle; and (ii) tazemetostat is to be administered twice daily starting on day 1 of the first 28-day cycle, wherein the NHL is relapsed or refractory DLBCL or relapsed or refractory FL;

(14) (i) the medicament is manufactured to be administered in cycles of once daily for 14 days followed by 14 days of rest, starting on day 1 of the first 28-day cycle; and (ii) tazemetostat

is to be administered twice daily starting on day 1 of the first 28-day cycle, wherein the NHL is relapsed or refractory DLBCL or relapsed or refractory FL; or

(15) (i) the medicament is manufactured to be administered in cycles of once daily for 21 days followed by 7 days of rest, starting on day 1 of the first 28-day cycle; and (ii) tazemetostat is to be administered twice daily starting on day 1 of the first 28-day cycle, wherein the NHL is relapsed or refractory DLBCL or relapsed or refractory FL.

34. The use of any one of claims 1 to 33, wherein the medicament is manufactured for further combination with granulocyte-colony stimulating factor (G-CSF) or granulocyte-macrophage colony stimulating factor (GM-CSF).

35. The use of claim 34, wherein the G-CSF is filgrastim or pegfilgrastim.

36. The use of claim 35, wherein filgrastim is to be administered in an amount of about 5 mcg/day/kg of the body weight of the subject.

37. The use of any one of claims 34 to 36, wherein the G-CSF is to be administered via subcutaneous or intravenous injection.

38. The use of any one of claims 34 to 37, wherein G-CSF is to be administered on days 15 to 28 of a 28-day cycle whereas the medicament is manufactured to be administered on days 1 to 14 of the 28-day cycle; or the G-CSF is to be administered on days 8 to 14 and days 22 to 28 of a 28-day cycle whereas the medicament is manufactured to be administered on days 1 to 7 and days 15 to 21 of the 28-day cycle.